XRCC6P5 and glioblastoma: On a non-gynecological cancer example, there is emerging evidence that the use of PARPis can potentiate the action of alkylating agents in glioblastoma tumors that have hypermethylation of the promoter of MGMT, coding for another DNA repair protein [33].